Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting…
Read MoreBreaking developments in psychiatric research and updates from Psychopharmacology Bulletin.
A study of 1.5 million UK adults found that autoimmune diseases are linked to a nearly twofold increase in the risk for mood disorders such as depression, anxiety, and bipolar…
Read More
Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer's disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records…
Read MoreAn international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report 'set and setting,' the…
Read More
A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder.…
Read MorePsychological therapy has been shown to significantly alleviate depression and anxiety in stroke survivors, particularly when initiated within six months of the stroke event. In a study involving over 7,000…
Read MoreSynthetic psilocybin demonstrates a significant reduction in treatment-resistant depression symptoms
A Phase 3 clinical trial of COMP360, a synthetic formulation of psilocybin, showed a significant reduction in symptoms of treatment-resistant depression. Conducted at 32 sites across the U.S. with 258…
Read MoreTwo new studies examining mental health risks postpartum were published online in the American Journal of Psychiatry in conjunction with Maternal Mental Health Awareness Month and the 2025 Annual Meeting…
Read MoreA novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels of…
Read MoreNeurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025…
Read More